Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

New funding for glaucoma efforts
December 2019
SHARING OPTIONS:

NEW YORK—Q BioMed Inc. reported recently that Mannin, its technology partner, had been awarded a $7.5-million grant from the German state of Saxony. The grant will support the development of novel pharmaceuticals and biologic treatments for glaucoma. Mannin’s current efforts include preclinical development of a small-molecule pharmaceutical eye drop and a novel recombinant protein injectable biologic, and the company is exploring different administration methods and regimens to reduce intraocular pressure.
 
Denis Corin, CEO of Q BioMed, said, “We are thrilled that we will be able to speed the development of these promising therapeutics and bring new innovation to glaucoma patients as soon as possible. Our partnership with Mannin and now, the government of Saxony is important to the advancement of this unique drug platform and we look forward to supporting the build-out of the Mannin European headquarters in Leipzig.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.